A third-generation CAR-T cell therapy targeting c-Met, incorporating CD28, 4-1BB, and CD3ζ co-stimulatory domains, demonstrated antitumor efficacy in an orthotopic RCC mouse model, where tumor growth inhibition was observed in 60% of cases. This evidence concerns the gene MET and renal cell carcinoma.